Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd + nivolumab + capecitabine + oxaliplatin in HER2-low gastric/GEJ/esophageal adenocarcinoma
jRCT2031230477Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan, nivolumab, capecitabine and oxaliplatin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting toxicity incidence (Phase 1b) and Objective response rate (Phase 2). Started Nov 2023; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031230477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230477.